ERYTHROMYCIN PANPHARMA 500mg price in UAE

Overview

Welcome to Dwaey, specifically on ERYTHROMYCIN PANPHARMA 500mg Powder for solution for Infusion page.
This medicine contains an important and useful components, as it consists of Erythromycin.
ERYTHROMYCIN PANPHARMA 500mg is available in the market in concentration 500mg/Vial and in the form of Powder for solution for Infusion.

PANPHARMA is the producer of ERYTHROMYCIN PANPHARMA 500mg and it is imported from FRANCE, The most popular alternatives of ERYTHROMYCIN PANPHARMA 500mg are listed downward .

Mode Of Action

Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.

Indication

Acne

Precaution

Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis. Lactation: Unknown if excreted in breast milk; use with caution

Side Effects

Contact sensitization
Dryness
Erythema
Skin irritation
Skin tenderness Potentially Fatal: Hepatotoxicity
cholestatic jaundice; raised serum transaminases; eosinophilia.

Contra indication

Hypersensitivity; porphyria; hepatic impairment; pregnancy.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Rhabdomyolysis w/ or w/o renal impairment w/ HMG-CoA reductase inhibitors (e.g. simvastatin). Increased risk of colchicine toxicity. Increased sedation w/ triazolobenzodiazepines and related benzodiazepines (e.g. alprazolam, midazolam). Theophylline may decrease and cimetidine may increase erythromycin concentration. Hypotension, bradyarrhythmia and lactic acidosis w/ Ca channel blockers (e.g. verapamil, amlodipine, diltiazem). Increased systemic exposure of sildenafil. Increased or prolonged adverse effects w/ ciclosporin, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine and bromocriptine. Increased risk of digoxin toxicity. Increased bleeding w/ oral anticoagulants. Potentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.